Illumina’s new constellation map read technology was trialed with GeneDx to detect difficult‑to‑map genomic variants in rare‑disease samples. The pilot reportedly exceeded alternative methods in sensitivity across a range of sample types, suggesting the approach could close diagnostic gaps in clinical sequencing workflows. Presentations at the American Society for Human Genetics and a company PR highlighted improved variant calling for previously intractable regions. The pilot outcome has implications for diagnostic labs and rare‑disease pipelines that depend on higher‑confidence detection of structural and complex variants.